Full Text
Assessing The Cost-Effectiveness of Secukinumab Compared To Tnf Inhibitors As Second Line Biologic Treatment In Psoriatic Arthritis

Abstract

Authors

A Lang M Costa-Scharplatz A Fasth P Gunda SM Jugl L Jacobsson

Back to Volume 19, Issue 7
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×